Overview

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Turning Point Therapeutics, Inc.

Treatments:

Trametinib